MA54378A - Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine - Google Patents

Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine

Info

Publication number
MA54378A
MA54378A MA054378A MA54378A MA54378A MA 54378 A MA54378 A MA 54378A MA 054378 A MA054378 A MA 054378A MA 54378 A MA54378 A MA 54378A MA 54378 A MA54378 A MA 54378A
Authority
MA
Morocco
Prior art keywords
compounds used
heteroaromatic compounds
vanin
inhibitors
vanin inhibitors
Prior art date
Application number
MA054378A
Other languages
English (en)
Inventor
Martin Thomas Fleck
Cédrickx Godbout
Hannes Fiepko Koolman
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA54378A publication Critical patent/MA54378A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054378A 2018-12-03 2019-12-02 Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine MA54378A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18209721 2018-12-03

Publications (1)

Publication Number Publication Date
MA54378A true MA54378A (fr) 2022-03-09

Family

ID=64572152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054378A MA54378A (fr) 2018-12-03 2019-12-02 Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine

Country Status (26)

Country Link
US (3) US11078182B2 (fr)
EP (1) EP3891139A1 (fr)
JP (2) JP7130873B2 (fr)
KR (1) KR20210100150A (fr)
CN (2) CN114478485B (fr)
AR (1) AR117229A1 (fr)
AU (1) AU2019391279B2 (fr)
BR (1) BR112021007915A2 (fr)
CA (1) CA3116830A1 (fr)
CL (2) CL2021001198A1 (fr)
CO (1) CO2021007173A2 (fr)
CR (1) CR20210294A (fr)
DO (1) DOP2021000071A (fr)
EA (1) EA202191476A1 (fr)
EC (1) ECSP21040278A (fr)
IL (1) IL283397B2 (fr)
JO (2) JOP20210127A1 (fr)
MA (1) MA54378A (fr)
MX (1) MX2021006520A (fr)
PE (1) PE20211769A1 (fr)
PH (1) PH12021551280A1 (fr)
SA (1) SA521422152B1 (fr)
SG (1) SG11202104437XA (fr)
TW (1) TWI838430B (fr)
UA (1) UA128374C2 (fr)
WO (1) WO2020114943A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019326933B2 (en) 2018-08-28 2024-12-05 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
JP7558942B2 (ja) 2018-11-30 2024-10-01 コメット セラピューティクス インコーポレイテッド パンテテイン誘導体及びその使用
EA202191476A1 (ru) * 2018-12-03 2021-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Гетероароматические соединения в качестве ингибиторов ванина
AU2019392524B2 (en) * 2018-12-03 2025-05-08 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
US12358910B2 (en) 2018-12-03 2025-07-15 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
WO2021174024A1 (fr) 2020-02-28 2021-09-02 First Wave Bio, Inc. Méthodes de traitement de la colite auto-immune iatrogène
WO2023174409A1 (fr) * 2022-03-18 2023-09-21 上海美悦生物科技发展有限公司 Forme de sel et forme cristalline d'inhibiteur d'enzyme de vanine, leur procédé de préparation et leur utilisation
WO2024196841A1 (fr) * 2023-03-21 2024-09-26 Athos Therapeutics, Inc. Inhibiteurs de vanine-1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2540868A1 (fr) 2003-10-09 2005-04-21 Abbott Laboratories Derives de pyrrolidinyle- uree utilises comme inhibiteurs de l'angiogenese
CA2885778A1 (fr) 2012-09-25 2014-04-03 Mathilde Muzerelle Alpha-hydroxy-amides
US10308615B2 (en) 2015-05-29 2019-06-04 Pfizer Inc. Heterocyclic compounds as inhibitors of Vanin-1 enzyme
WO2018011681A1 (fr) * 2016-07-14 2018-01-18 Pfizer Inc. Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
AU2018285131B2 (en) 2017-06-12 2021-11-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
AU2019326933B2 (en) 2018-08-28 2024-12-05 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
EA202191476A1 (ru) * 2018-12-03 2021-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Гетероароматические соединения в качестве ингибиторов ванина
AU2019392524B2 (en) * 2018-12-03 2025-05-08 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
US12358910B2 (en) * 2018-12-03 2025-07-15 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors

Also Published As

Publication number Publication date
TWI838430B (zh) 2024-04-11
IL283397B1 (en) 2024-11-01
CN113166104A (zh) 2021-07-23
EA202191476A1 (ru) 2021-10-26
UA128374C2 (uk) 2024-06-26
SA521422152B1 (ar) 2023-12-05
JOP20210128A1 (ar) 2023-01-30
PE20211769A1 (es) 2021-09-07
WO2020114943A1 (fr) 2020-06-11
CL2021001198A1 (es) 2021-12-24
PH12021551280A1 (en) 2021-12-06
CO2021007173A2 (es) 2021-06-21
ECSP21040278A (es) 2021-07-30
CR20210294A (es) 2021-08-13
MX2021006520A (es) 2021-07-07
SG11202104437XA (en) 2021-05-28
US20230295112A1 (en) 2023-09-21
EP3891139A1 (fr) 2021-10-13
DOP2021000071A (es) 2021-05-31
IL283397B2 (en) 2025-03-01
AU2019391279B2 (en) 2025-02-20
US11078182B2 (en) 2021-08-03
TW202039461A (zh) 2020-11-01
JP2022509317A (ja) 2022-01-20
CL2021003568A1 (es) 2022-11-04
CN114478485A (zh) 2022-05-13
US20200172508A1 (en) 2020-06-04
AR117229A1 (es) 2021-07-21
AU2019391279A1 (en) 2021-05-13
JP7130873B2 (ja) 2022-09-05
US20220048885A1 (en) 2022-02-17
JP2022188014A (ja) 2022-12-20
CA3116830A1 (fr) 2020-06-11
IL283397A (en) 2021-07-29
CN114478485B (zh) 2024-04-05
JOP20210127A1 (ar) 2023-01-30
BR112021007915A2 (pt) 2021-07-27
KR20210100150A (ko) 2021-08-13

Similar Documents

Publication Publication Date Title
MA54378A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA56398A (fr) Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
EP3621624A4 (fr) Composés dinucléotidiques cycliques en tant qu'agonistes sting
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA51610A (fr) Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA49956A (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
EP3733673A4 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
EP3442488A4 (fr) Compositions pour l'application topique de composés
EP3442973A4 (fr) Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant